PRELUDE CAPITAL MANAGEMENT, LLC - JOUNCE THERAPEUTICS INC ownership

JOUNCE THERAPEUTICS INC's ticker is JNCE and the CUSIP is 481116101. A total of 100 filers reported holding JOUNCE THERAPEUTICS INC in Q4 2019. The put-call ratio across all filers is 0.88 and the average weighting 1.0%.

Quarter-by-quarter ownership
PRELUDE CAPITAL MANAGEMENT, LLC ownership history of JOUNCE THERAPEUTICS INC
ValueSharesWeighting
Q1 2022$100,000
-6.5%
14,800
+15.6%
0.00%0.0%
Q4 2021$107,000
+37.2%
12,800
+12.3%
0.00%
+50.0%
Q2 2021$78,000
+3800.0%
11,400
+5600.0%
0.00%
Q3 2020$2,000
-94.7%
200
-95.3%
0.00%
-100.0%
Q4 2019$38,000
+81.0%
4,300
+30.6%
0.00%0.0%
Q3 2018$21,000
+16.7%
3,293
+43.2%
0.00%0.0%
Q2 2018$18,0002,3000.00%
Other shareholders
JOUNCE THERAPEUTICS INC shareholders Q4 2019
NameSharesValueWeighting ↓
TRV GP II, LLC 9,200,349$64,402,00044.86%
TRV GP III, LLC 3,048,780$21,342,0001.83%
SILVERARC CAPITAL MANAGEMENT, LLC 406,665$2,847,0001.65%
Sofinnova Investments, Inc. 925,280$6,477,0000.39%
Omega Fund Management, LLC 334,965$2,345,0000.35%
Yorktown Management & Research Co Inc 49,200$344,0000.31%
Woodline Partners LP 940,902$6,586,0000.18%
HUSSMAN STRATEGIC ADVISORS, INC. 51,000$357,0000.09%
HORIZON FINANCIAL SERVICES, LLC 12,005$84,0000.08%
Gyon Technologies Capital Management, LP 26,893$188,0000.06%
View complete list of JOUNCE THERAPEUTICS INC shareholders